美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ALPS Medical Breakthroughs ETF

67.66

+0.35000.52%

盤後：67.660.00000.00%19:51 EDT

成交量：2.67萬

成交額：179.78萬

市值：2.44億

市盈率：- -

高：67.67

開：66.98

低：66.96

收：67.31

52周最高：70.85

52周最低：35.43

股本：360.00萬

流通股本：360.00萬

量比：0.81

換手率：0.74%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

109億美元重磅收購Apogee(APGE.US)落地！艾伯維(ABBV.US)完成2019年以來最大併購，預計2032年起貢獻收益

109億美元重磅收購Apogee(APGE.US)落地！艾伯維(ABBV.US)完成2019年以來最大併購，預計2032年起貢獻收益

美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極

藥聞 | 英硅智能上市後首份半年報扭虧創新藥研發加速擁抱AI

聯環藥業上半年扭虧為盈集採續採與創新藥研發協同推進

博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

東方證券：AI重構創新藥研發底座國內相關產業鏈公司亦有望受益

券商觀點：艾伯維免疫學研發管線實力雄厚，將支撐營收增長

艾伯維因收購Apogee下調2026年盈利預期，第二季度業績超出預期

《健康快訊》：實驗性細胞療法可延緩杜氏肌營養不良症患者心力衰竭的進展

創新藥研發加速遇「猴荒」

ANI Pharmaceuticals 宣佈擬就CG Oncology相關裁決提出上訴

英硅智能早盤升逾7% 與康哲藥業達成AI+創新藥研發新合作

（活力中國調研行）上海生物醫藥產業規模破萬億張江藥谷青年人才成創新藥研發主力

中国新闻网

翰思艾泰-B(03378)：擬與華科前沿交叉研究中心打造新一代AI驅動的創新藥研發範式

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/SBIO/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","market":"US","secType":"STK","nameCN":"ALPS Medical Breakthroughs ETF","latestPrice":67.66,"timestamp":1788552000000,"preClose":67.31,"halted":0,"volume":26679,"hourTrading":{"tag":"盘后","latestPrice":67.66,"preClose":67.66,"latestTime":"19:51 EDT","volume":124,"amount":8385.21,"timestamp":1788565888060,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.005199821720398073,"floatShares":3600000,"shares":3600000,"eps":0,"marketStatus":"已收盤","change":0.35,"latestTime":"09-04 16:00:00 EDT","open":66.98,"high":67.665,"low":66.96,"amount":1797845.892666,"amplitude":0.010474,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":67.31,"sharesOutstanding":2675000,"nav":67.36,"aum":242478255.23,"bidAskSpread":0.001889,"preHourTrading":{"tag":"盘前","latestPrice":67.57,"preClose":67.31,"latestTime":"07:37 EDT","volume":3,"amount":202.70999999999998,"timestamp":1788521835899,"change":0.26,"changeRate":0.003863,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":67.66,"preClose":67.66,"latestTime":"19:51 EDT","volume":124,"amount":8385.21,"timestamp":1788565888060,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.807192,"impliedVol":0.2138,"impliedVolPercentile":0.6825},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","floatShares":3600000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.807192,"shares":3600000,"dividePrice":0,"high":67.665,"amplitude":0.010474,"preClose":67.31,"low":66.96,"week52Low":35.43,"pbRate":"--","week52High":70.85,"institutionHeld":0,"latestPrice":67.66,"eps":0,"divideRate":0,"volume":26679,"delay":0,"ttmEps":0,"open":66.98,"prevYearClose":51.22,"prevWeekClose":67.09,"prevMonthClose":66.82,"prevQuarterClose":64.65,"fiveDayClose":67.09,"twentyDayClose":67.614,"sixtyDayClose":50.5209},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBIO\",params:#limit:5,,,undefined,":[{"date":"2024-12-19","symbol":"SBIO","amount":1.17346,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-19","defaultRemindTime":1734618600000,"name":"ALPS Medical Breakthroughs ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-19","currency":"USD","dateTimestamp":1734584400000,"payDate":"2024-12-26"},{"date":"2023-12-21","symbol":"SBIO","amount":0.07106,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-22","defaultRemindTime":1703169000000,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2023-12-27","payableDate":"2023-12-22","currency":"USD","dateTimestamp":1703134800000,"payDate":"2023-12-27"},{"market":"US","date":"2019-12-19","symbol":"SBIO","amount":0.01585,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2019-12-27","payableDate":"2019-12-20","currency":"USD","type":"dividend","dateTimestamp":1576731600000},{"market":"US","date":"2018-12-20","symbol":"SBIO","amount":0.78406,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2018-12-27","payableDate":"2018-12-21","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBIO\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.78406,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":"2019-12-27","value":0.01585,"currency":"USD"},{"executeDate":"2023-12-21","recordDate":"2023-12-22","paymentDate":"2023-12-27","value":0.07106,"currency":"USD"},{"executeDate":"2024-12-19","recordDate":"2024-12-19","paymentDate":"2024-12-26","value":1.17346,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBIO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBIO\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664388058","title":"109億美元重磅收購Apogee(APGE.US)落地！艾伯維(ABBV.US)完成2019年以來最大併購，預計2032年起貢獻收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664388058?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B19Z3B42.SGD","PJP","JDOC","TRUH","LU0124676726.USD","LU2129689605.HKD","SG9999003800.SGD","LU1267930490.SGD","ABBV","XLV","SBIO","IE0002141913.USD","APGE","LU1839511570.USD","PPH","CALF","LU1551013425.SGD","LU0320765646.SGD","LU0170899867.USD","LU1496350502.SGD","IXJ","LU0128525929.USD","BK4533","IE000WAW04H5.SGD","LU2087621335.USD","LU2089984988.USD","XMMO","MYLD","VHT","LU1236620834.HKD","LU0820561909.HKD","FTXH","RXL","LU2237443895.HKD","KCE","LU0203345920.USD","LU0859254822.USD","LU0114720955.EUR","LU2129689514.USD","AGNG","MEDX","IYH","LU0069063385.USD","LU2125909593.SGD","LU2433249047.HKD","GLAM","FHLC","LU0234570918.USD","LU0310800379.SGD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664053388","title":"109億美元重磅收購Apogee(APGE.US)落地！艾伯維(ABBV.US)完成2019年以來最大併購，預計2032年起貢獻收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664053388","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664053388?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维于周四表示，公司已完成对抗炎药物研发商 Apogee Therapeutics价值 109 亿美元的收购。笔交易是这家制药巨头自 2019 年以来规模最大的补强型收购，智通财经AAPP于今年 6 月首次对此进行了报道。艾伯维预计，该项收购将对其调整后稀释每股收益产生负面影响，其中 2026 年将减少 0.14 美元，2027 年减少约 0.46 美元，并预计将于 2032 年开始实现增益。该指引已包含与完成 Apogee 收购相关的每股 0.14 美元稀释效应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4559","LU1934455194.USD","KCE","LU1718418525.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IXJ","LU0124676726.USD","IYH","APGE","XMMO","BK4566","LU1989772840.SGD","PJP","AGNG","SG9999011175.SGD","ABBV","VHT","LU0965509283.SGD","LU0170899867.USD","IE00BLSP4239.USD","IE0002270589.USD","CALF","LU1003077747.HKD","FHLC","LU0289739343.SGD","LU2089283258.USD","IE00BN8TJ469.HKD","LU1037948541.HKD","BK4581","TRUH","LU0203345920.USD","IE0004445239.USD","LU0985320562.USD","MEDX","LU1983299246.USD","FTXH","JDOC","GLAM","XLV","SBIO","LU0256863902.USD","LU2237443549.SGD","PPH","RXL","IE00B19Z3581.USD","LU0057025933.USD","MYLD","LU1093756168.USD","LU1236620834.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00B4R5TH58.HKD","LU2272731600.USD","LU2473716301.USD","IE00BJJMRZ35.SGD","RXL","MRNY","PBPH","PPH","IBB","SBIO","BBH","IE0002141913.USD","TMED","HELX","LU0070302665.USD","BBP","FBT","BIB","IYH","MEDX","PJP","NVS","LU0211331839.USD","RSPH","SYNB","BIOY","XPH","AZNH","BK4588","FTXH","PSCH","IEHS","CANC","BME","LU2322448957.HKD","IE0009355771.USD","IEIH","XBIX","MRNX","IBRN","LFSC","WDNA","GNOM","IE00BJT1NW94.SGD","IDNA","MEDI","PBE","BK4585","IE00BFTCPJ56.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GDOC","AGIX","PBE","QTOC","XLVI","BBP","LFSC","BIOY","GSKH","BK4588","APXH","AIPO","IBB","BK4585","SBIO","WRND","IPOS","ARTY","VTHR","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GDOC","BBP","BK0239","600513","WRND","XLVI","PBE","LFSC","GSKH","BK4588","APXH","BK4585","IBB","BIOY","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["GDOC","SPHQ","IBB","SBIO","BK0216","GSKH","159399","LFSC","XLVI","BIOY","WRND","BBP","BK4585","300404","APXH","PBE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LFSC","GSKH","BK1147","XLVI","06881","APXH","BK4588","SBIO","BK4585","IBB","PBE","161027","BK0276","BK1564","BK0188","GDOC","BBP","BIOY","WRND","601881"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SBIO","BK4585","LFSC","BK0216","GDOC","APXH","PBE","WRND","XLVI","BK4588","BIOY","GSKH","IBB","BK0102","600721","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["APXH","SBIO","LFSC","GDOC","GSKH","BK4585","IBB","BIOY","WRND","BBP","XLVI","BK4588","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["WRND","GDOC","BIOY","BK4588","BK4585","XLVI","SBIO","IBB","BBP","BK0102","GSKH","APXH","LFSC","PBE","BK0216","600721"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"東方證券：AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ARTY","BK1564","SBIO","AGIX","BK0012","VTHR","AIPO","BK1147","QTOC","IBB","BK0276","GDOC","03958","WRND","XLVI","BK0183","BK4588","BK0028","GSKH","LFSC","APXH","BK4585","CHAT","BIOY","BK0188","600958","PBE","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375158","title":"券商觀點：艾伯維免疫學研發管線實力雄厚，將支撐營收增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375158","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375158?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 19:32","pubTimestamp":1785756750,"startTime":"0","endTime":"0","summary":"BUZZ-券商观点：艾伯维免疫学研发管线实力雄厚，将支撑营收增长8月3日-** 艾伯维（AbbVie）ABBV.N周五略微下调了其2026年盈利预期 (link)，以反映其计划收购Apogee Therapeutics的交易；同时，得益于免疫学药物销售强劲，该公司第二季度业绩超出市场预期免疫学业务表现稳健** Canaccord Genuity(维持“买入”评级，目标价：290美元) 指出，艾伯维","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL4S4400YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","TRUH","PPH","LU0417517546.SGD","LU2089283258.USD","RXL","FHLC","FTXH","LU0726765562.USD","LU1061106388.HKD","LU1093756325.SGD","LU1989772923.USD","LU0029864427.USD","LU1496350171.SGD","LU2237443978.SGD","LU0965508806.USD","ABBV","IE00BGHQF631.EUR","IE0004445239.USD","LU0211327993.USD","GLAM","IXJ","JDOC","LU1093756168.USD","VHT","AGNG","LU0689472784.USD","LU1670627923.USD","XLV","BK4534","LU1551013425.SGD","LU1267930490.SGD","LU0203345920.USD","IE00BLSP4452.SGD","PJP","IE00BJJMRZ35.SGD","APGE","IE00BVYPNV92.GBP","LU0053671581.USD","BK4533","LU0198837287.USD","MEDX","LU0912757837.SGD","SG9999003800.SGD","LU1003077747.HKD","LU0661504455.SGD","IYH","LU0472753341.HKD","LU1267930573.SGD","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655365569","title":"艾伯維因收購Apogee下調2026年盈利預期，第二季度業績超出預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655365569","media":"路透中文","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655365569?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 19:49","pubTimestamp":1785498540,"startTime":"0","endTime":"0","summary":"艾伯维因收购Apogee下调2026年盈利预期，第二季度业绩超出预期预计2026年每股收益将因计划中的Apogee收购交易而减少14美分季度营收超出预期，达到169.9亿美元Humira销售额下滑36%至7.56亿美元，仍高于市场预期Skyrizi和Rinvoq的业绩也超出预期路透7月31日-艾伯维ABBV.N周五下调了2026年的盈利预期，以反映其计划收购Apogee Therapeutics的影响，同时得益于免疫学药物销售强劲，其第二季度业绩超出市场预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4S43X1CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU0820561909.HKD","SG9999015952.SGD","PPH","APGE","IE00BSNM7G36.USD","RXL","FHLC","TRUH","IE0002141913.USD","LU0738911758.USD","IE00BVYPNW00.USD","FTXH","GLAM","LU0689626769.HKD","LU0689472784.USD","LU2129689431.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU1839511570.USD","PJP","MEDX","LU0203347892.USD","VHT","AGNG","IYH","LU0456855351.SGD","LU2087621335.USD","LU1732800096.USD","LU1718418525.SGD","LU0965509283.SGD","IXJ","LU1037948541.HKD","LU0170899867.USD","ABBV","IE000BZT7R73.USD","LU2347655156.SGD","SG9999015945.SGD","IE00B19Z3B42.SGD","LU1061106388.HKD","SBIO","IE000MB6IJN5.SGD","BK4588","JDOC","LU0122379950.USD","LU0211328371.USD","BK4559","XLV","LU1551013425.SGD","LU1670628061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655480022","title":"《健康快訊》：實驗性細胞療法可延緩杜氏肌營養不良症患者心力衰竭的進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2655480022","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655480022?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 02:56","pubTimestamp":1785437766,"startTime":"0","endTime":"0","summary":"研究人员表示，这些数据标志着首次有治疗方法被证实不仅能减缓或阻止上肢功能的丧失，还能延缓杜氏肌营养不良症患儿及年轻男性患者心力衰竭的进展。杜氏肌营养不良症是一种遗传性疾病，会导致全身肌肉逐渐萎缩，而心力衰竭往往会导致患者过早死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL4S43W2K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SBIO","CAPR","CGON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"創新藥研發加速遇「猴荒」","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653584157?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["WRND","GDOC","BIOY","BK4588","BK4585","XLVI","SBIO","IBB","BBP","GSKH","APXH","LFSC","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196709641","title":"ANI Pharmaceuticals 宣佈擬就CG Oncology相關裁決提出上訴","url":"https://stock-news.laohu8.com/highlight/detail?id=1196709641","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196709641?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 06:34","pubTimestamp":1784241277,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals Inc. 宣布，计划就与CG Oncology Inc.相关诉讼中的裁决提出上诉。此前，初审法院已驳回该公司提出的重新审理及判决的动议。\n该公司表示，将继续寻求追回其在2010年出售给CG Oncology的资产价值。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","SBIO","LU0566484027.USD","CGON","BK4139","ANIP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盤升逾7% 與康哲藥業達成AI+創新藥研發新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651162210?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":"　　英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。　　7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。　　根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BMCWC346.EUR","BK1593","IE00BVYPNQ40.USD","BK1191","AIPO","BK4585","SG9999015945.SGD","BK4588","00867","GSKH","LFSC","IE00BVYPNP33.GBP","SBIO","AGIX","IBB","IE00BYV24P56.USD","ARTY","WRND","SG9999004220.SGD","QTOC","IE00BGHQDM52.EUR","SG9999015952.SGD","GDOC","SG9999015986.USD","CHAT","PBE","LU2488822045.USD","SG9999015978.USD","BBP","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649952006","title":"（活力中國調研行）上海生物醫藥產業規模破萬億 張江藥谷青年人才成創新藥研發主力","url":"https://stock-news.laohu8.com/highlight/detail?id=2649952006","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649952006?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 11:56","pubTimestamp":1783482969,"startTime":"0","endTime":"0","summary":"中新网上海7月8日电(杨海燕马佳佳)“我们对青年人才‘如饥似渴’，上海团队有180多名全职员工，90%以上都是40岁以下的青年人才。”英硅智能全球对外合作负责人、副总裁王珏7日在“活力中国调研行”主题采访活动中介绍道。在上海张江药谷，这片曾经的农田已崛起为世界级生物医药创新高地，而活跃其中的青年人才，正成为推动创新药研发的主力军。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798154946.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","399441","WRND","BK4581","BK4588","LFSC","SBIO","BBP","GDOC","PBE","IBB","161726","XBI","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984355","title":"翰思艾泰-B(03378)：擬與華科前沿交叉研究中心打造新一代AI驅動的創新藥研發範式","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984355","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984355?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 18:57","pubTimestamp":1783421872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，为充分发挥产学研结合的优势，加速生物医药研发创新，公司于近日与华科—澳城大高等研究院前沿交叉研究中心正式签署了《“人工智能药物研发联合实验室”合作共建协议》。双方将依托华科前沿交叉研究中心的AI平台，以及翰思艾泰在创新药研发的丰富经验和对疾病领域的深度认知，围绕抗体发现与分子设计展开深度合作，共同打造新一代AI驱动的创新药研发范式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SBIO","BK4588","VTHR","PBE","GSKH","BK1535","WRND","BBP","BK1173","IBB","CHAT","AIPO","GDOC","03378","QTOC","BK1161","LFSC","AGIX","ARTY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}